Abstract
This is a study evaluating the efficacy of Ankaferd Blood Stopper (ABS) as a hemostatic agent compared to hemostasis by phenylephrine in patients with anterior epistaxis. The study design is a prospective, randomized, controlled, nonblinded, clinical trial. In total, 49 patients were randomly seperated to receive hemostasis technique by means of either ABS wet tampon or phenylephrine impregnated gauze tampon for anterior epistaxis control. Patients were crossed over to the other technique after two unsuccessful attempts of the first technique. Measured outcomes such as number of applications, relationship of number of applications with bleeding intensity (1 = stains on napkin, 2 = soaked napkin, 3 = bowl needed), patient discomfort during hemostasis (0 = none, 9 = unbearable), and complications were assessed. Additional data were recorded for rebleeding within 7 days. 24 of the 49 patients were assigned to the new ABS group (group I) and remaining 25 were included in the standard phenylephrine group (group II). ABS was more effective than phenylephrine at control of anterior epistaxis (79.2 vs. 64%, p < 0.05). For the patients who crossed over from phenylephrine to ABS, 44.4% achieved hemostasis by ABS. ABS successfully treated all bleeding intensity 1 and 2 patients with one application (5 min). ABS patients experienced fewer rebleeding rates within 7 days compared to phenylephrine patients (8.3 vs. 20%, p < 0.05). The patients for which ABS was applied, significant differences in effective control of anterior epistaxis were observed compared to phenylephrine. ABS is effective, safe, quick, and easy alternative to the phenylephrine in patients with anterior epistaxis.
Similar content being viewed by others
References
Duncan IC, Fourie PA, le Grange CE, van der Walt HA (2004) Endovascular treatment of intractable epistaxis—results of a 4-year local audit. S Afr Med J 94:373–378
Viehweg TL, Roberson JB, Hudson JW (2006) Epistaxis: diagnosis and treatment. J Oral Maxillofac Surg 64:511–518
Goker H, Haznedaroglu IC, Ercetin S, Kirazli S, Akman U, Ozturk Y, Firat HC (2008) Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper. J Int Med Res 36:163–170
Bilgili H, Kosar A, Kurt M et al (2009) Hemostatic efficacy of Ankaferd Blood Stopper in a swine bleeding model. Med Princ Pract 18:165–169
Bergler W, Sadick H, Gotte K, Riedel F, Hörmann K (2002) Topical estrogens combined with argon plasma coagulation in the management of epistaxis in hereditary hemorrhagic telangiectasia. Ann Otol Rhinol Laryngol 111:222–228
Willems PW, Farb RI, Agid R (2009) Endovascular treatment of epistaxis. AJNR Am J Neuroradiol 30:1637–1645
Kucik CJ, Clenney T (2005) Management of epistaxis. Am Fam Physician 71:305–311
Bhatnagar RK, Berry S (2004) Selective surgicel packing for the treatment of posterior epistaxis. Ear Nose Throat J 83:633–634
Huggins S (1969) Control of hemorrhage in otorhinolaryngologic surgery with oxidized regenerated cellulose. Eye Ear Nose Throat Mon 48:420–423
Mathiasen RA, Cruz RM (2005) Prospective, randomized, controlled clinical trial of a novel matrix hemostatic sealant in patients with acute anterior epistaxis. Laryngoscope 115:899–902
Aydin S (2009) Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper. J Int Med Res 37:279
Cipil HS, Kosar A, Kaya A et al (2009) In vivo hemostatic effect of the medicinal plant extract Ankaferd Blood Stopper in rats pretreated with warfarin. Clin Appl Thromb Hemost 15:270–276
Kurt M, Disibeyaz S, Akdogan M, Sasmaz N, Aksu S, Haznedaroglu IC (2008) Endoscopic application of Ankaferd Blood Stopper as a novel experimental treatment modality for upper gastrointestinal bleeding: a case report. Am J Gastroenterol 103:2156–2158
Kurt M, Kacar S, Onal IK, Akdogan M, Haznedaroglu IC (2008) Ankaferd Blood Stopper as an effective adjunctive hemostatic agent for the management of life-threatening arterial bleeding of the digestive tract. Endoscopy 40:262
Ibis M, Kurt M, Onal IK, Haznedaroglu IC (2008) Successful management of bleeding due to solitary rectal ulcer via topical application of Ankaferd Blood Stopper. J Altern Complement Med 14:1073–1074
Bilgili H, Captug O, Kosar A, et al (2009) Oral systemic administration of Ankaferd Blood Stopper has no short-term toxicity in an in vivo rabbit experimental model. Clin Appl Thromb Hemost July 14 [Epub ahead of print]
Conflict of interest statement
We do not have a financial relationship with any organization.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Meric Teker, A., Korkut, A.Y., Kahya, V. et al. Prospective, randomized, controlled clinical trial of Ankaferd Blood Stopper in patients with acute anterior epistaxis. Eur Arch Otorhinolaryngol 267, 1377–1381 (2010). https://doi.org/10.1007/s00405-010-1208-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00405-010-1208-0